Capricor Therapeutics, Inc. (CAPR)

Market Cap	1.72B +189.8%
Revenue (ttm)	n/a
Net Income	-105.04M
EPS	-2.26
Shares Out	57.51M
PE Ratio	n/a
Forward PE	111.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	696,069
Open	29.44
Previous Close	29.90
Day's Range	29.09 - 30.25
52-Week Range	4.30 - 40.37
Beta	0.48
Analysts	Strong Buy
Price Target	44.63 (+49.02%)
Earnings Date	Mar 12, 2026

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 231
• Stock Exchange: NASDAQ
• Ticker Symbol: CAPR
• Website: https://www.capricor.com

Analyst Summary

According to 8 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price target is $44.63, which is an increase of 49.02% from the latest price.

Price Target

$44.63

(49.02% upside)

Analyst Consensus: Strong Buy